Detalles de la búsqueda
1.
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Cancer
; 124(24): 4667-4675, 2018 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30383906
2.
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Lancet
; 384(9944): 665-73, 2014 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24933332
3.
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Lung Cancer
; 112: 126-133, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29191585
4.
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Lung Cancer
; 93: 95-103, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26898621
5.
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
J Natl Cancer Inst
; 106(7)2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25031274
6.
Superior vena cava stent migration into the pulmonary artery causing fatal pulmonary infarction.
Cardiovasc Intervent Radiol
; 34 Suppl 2: S198-201, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20135125
Resultados
1 -
6
de 6
1
Próxima >
>>